CNIC establishes global partnership with Isotopia to put patients first

Isotopia – a private Canadian funded international developer of short-lived, injectable PET and SPECT radiopharmaceuticals, isotopes for therapy and cold kit manufacturer- has partnered with the Canadian Nuclear Isotope Council, an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups, to demonstrate international collaboration in ensuring a reliable and secure supply of life-saving, medical isotopes.

“Every year over 40 million nuclear medicine procedures are performed, and the demand for radioisotopes is increasing rapidly especially in the emerging field of Theranostics.

 Lu-177 is only the first swallow, The need for other therapy isotopes like Alfa emitters is increasing.” said Dr. Eli Shalom, CEO of Isotopia. “Underpinning this increase in demand is the need for collaboration beyond borders that puts patients first and ensures that there is a reliable, secure and uninterrupted supply of critical life-saving medical isotopes. Our mission is to develop and manufacture the best treatments with different isotopes to patients globally”.

“The technologies we are developing are significant because they will enable physicians to make a better diagnosis, therapy, and allow for more precise and accurate treatment of cancers using medical isotopes. This is why we support the mandate of the CNIC, why we believe there are clear and distinct benefits to collaboration with our Canadian partners involved in this sector, ensuring no patient is left without access to life-saving cancer treatment.”

James Scongack, Chair of the CNIC, said today’s announcement is another step for Canada’s leadership role in the fight against cancer and disease.

“Our work isn’t nearly done,” said Scongack. “Cancer sees no borders and neither should cancer care and putting patients first. Today, more than 10,000 hospitals around the world use medical isotopes for sterilization, diagnostic imaging and cancer treatment. Investments in cancer control, including prevention, early detection and treatment, have all played a role in increasing the overall survival rate in cancer patients from about 25 per cent in the 1940s to 60 per cent today.

“Continuing to make those investments is critical at a time when the Canadian Cancer Society predicts that one in two Canadians will be diagnosed with cancer in their lifetime. That is why now is the time to make a renewed commitment to finding new partners to improve people’s lives.”

In its latest report, the CNIC identified that guarding and supporting our nuclear knowledge is important to the majority of Canadians for both our health care and safety.

The Canadian Nuclear Isotope Council recognizes the opportunity presented by continued Canadian leadership in isotope development, which is why it serves as a voice in safeguarding the continued availability of isotopes, ensuring our public policies are risk-informed and science-based, and support the highest levels of public health and safety.

About Eckert & Ziegler.

The Eckert & Ziegler Group is one of the world’s largest providers of isotope technology for medical, scientific and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry and nuclear-medical imaging. The Group is an international leader in some of its fields. The company employs around 800 people at 20 locations worldwide, 240 of them are working at the headquarters in Berlin-Buch. Eckert & Ziegler has been listed on the stock exchange since 1999 and is listed in the Prime Standard of the German Stock Exchange in Frankfurt am Main (ISIN DE0005659700).
Contributing to saving lives.

For more information, please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
49 (0) 30 / 94 10 84-138, ,

For more information, please contact:

Isotopia LTD Tel: (972)-3-9130314

Picture of Keren Moshkoviz

Keren Moshkoviz

Business Development Manager

All Posts

More To Explore